Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,409 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05533697 | Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 361 | ModernaTX, Inc.INDUSTRY | 7 | Jul 14, 2026 | clinicaltrials |
| NCT05650632 | A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 | 210 | AbbVieINDUSTRY | 7 | Jul 13, 2026 | clinicaltrials |
| NCT07109219 | Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia(ALLight) | recruiting | Phase 1 / Phase 2 | 83 | AstraZenecaINDUSTRY | 9 | Jul 13, 2026 | clinicaltrials |
| NCT07498725 | A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of LRK-4189 Alone and in Combination in Patients With Solid Tumors | recruiting | Phase 1 / Phase 2 | 120 | LARKSPUR BIOSCIENCES, INC.INDUSTRY | 2 | Jul 13, 2026 | clinicaltrials |
| NCT02813135 | European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors(ESMART) | recruiting | Phase 1 / Phase 2 | 472 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 6 | Jul 10, 2026 | clinicaltrials |
| NCT05403450 | A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL) | terminated | Phase 1 | 33 | Taiho Oncology, Inc.INDUSTRY | 7 | Jul 9, 2026 | clinicaltrials |
| NCT05413421 | Study of ORIC-944 in Patients With Metastatic Prostate Cancer | recruiting | Phase 1 | 275 | ORIC PharmaceuticalsINDUSTRY | 4 | Jul 9, 2026 | clinicaltrials |
| NCT04328844 | A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers | active not recruiting | Phase 1 | 210 | iOncturaINDUSTRY | 2 | Jul 8, 2026 | clinicaltrials |
| NCT06478212 | Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma | active not recruiting | Phase 1 / Phase 2 | 51 | Institut de Recherches Internationales ServierOTHER | 11 | Jul 8, 2026 | clinicaltrials |
| NCT06217822 | First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)(PAnTHA) | recruiting | Phase 1 | 198 | BayerINDUSTRY | 10 | Jul 7, 2026 | clinicaltrials |
| NCT06796907 | A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2) | recruiting | Phase 1 / Phase 2 | 305 | GlaxoSmithKlineINDUSTRY | 23 | Jul 7, 2026 | clinicaltrials |
| NCT02332668 | A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051) | recruiting | Phase 1 / Phase 2 | 370 | Merck Sharp & Dohme LLCINDUSTRY | 10 | Jul 6, 2026 | clinicaltrials |
| NCT03533283 | An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma | active not recruiting | Phase 1 / Phase 2 | 211 | Hoffmann-La RocheINDUSTRY | 6 | Jul 6, 2026 | clinicaltrials |
| NCT04389632 | A Study of Sigvotatug Vedotin in Advanced Solid Tumors | recruiting | Phase 1 | 1,006 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 7 | Jul 6, 2026 | clinicaltrials |
| NCT06254495 | A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers | terminated | Phase 1 | 58 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 6 | Jul 6, 2026 | clinicaltrials |
| NCT05131022 | A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies | recruiting | Phase 1 | 572 | Nurix Therapeutics, Inc.INDUSTRY | 8 | Jul 2, 2026 | clinicaltrials |
| NCT05489237 | First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors | active not recruiting | Phase 1 | 276 | IDRX, Inc., a wholly owned subsidiary of GSK, LLCINDUSTRY | 11 | Jul 2, 2026 | clinicaltrials |
| NCT07081646 | A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.(ALACRITY) | recruiting | Phase 1 / Phase 2 | 91 | Alexion Pharmaceuticals, Inc.INDUSTRY | 3 | Jul 2, 2026 | clinicaltrials |
| NCT05443126 | A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies | recruiting | Phase 1 / Phase 2 | 265 | Ellipses PharmaINDUSTRY | 8 | Jul 1, 2026 | clinicaltrials |
| NCT05571839 | A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors | terminated | Phase 1 | 41 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 6 | Jul 1, 2026 | clinicaltrials |
| NCT06179511 | Study of AZD9829 in CD123+ Hematological Malignancies | completed | Phase 1 / Phase 2 | 56 | AstraZenecaINDUSTRY | 10 | Jul 1, 2026 | clinicaltrials |
| NCT05720117 | A Study of PYX-201 in Advanced Solid Tumors | recruiting | Phase 1 | 330 | Pyxis Oncology, IncINDUSTRY | 4 | Jun 30, 2026 | clinicaltrials |
| NCT05938270 | A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer.(ASCERTAIN) | completed | Phase 1 | 113 | AstraZenecaINDUSTRY | 6 | Jun 30, 2026 | clinicaltrials |
| NCT02719574 | Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation | completed | Phase 1 / Phase 2 | 336 | Forma Therapeutics, Inc.INDUSTRY | 9 | Jun 29, 2026 | clinicaltrials |
| NCT03682276 | Safety and Bioactivity of Ipilimumab and Nivolumab Combination Prior to Liver Resection in Hepatocellular Carcinoma(PRIME-HCC) | completed | Phase 1 / Phase 2 | 33 | Imperial College LondonOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT05255601 | A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma(RELATIVITY-069) | terminated | Phase 1 / Phase 2 | 5 | Bristol-Myers SquibbINDUSTRY | 7 | Jun 26, 2026 | clinicaltrials |
| NCT03069469 | Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor | active not recruiting | Phase 1 / Phase 2 | 120 | Deciphera Pharmaceuticals, LLCINDUSTRY | 9 | Jun 25, 2026 | clinicaltrials |
| NCT05082259 | ASTEROID: A Trial of ASTX660 in Combination With Pembrolizumab(ASTEROID) | active not recruiting | Phase 1 | 61 | Institute of Cancer Research, United KingdomOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT05277051 | First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors | active not recruiting | Phase 1 | 152 | GlaxoSmithKlineINDUSTRY | 9 | Jun 25, 2026 | clinicaltrials |
| NCT06431594 | A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1) | recruiting | Phase 1 | 675 | GlaxoSmithKlineINDUSTRY | 15 | Jun 25, 2026 | clinicaltrials |
| NCT04068597 | Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies | recruiting | Phase 1 / Phase 2 | 250 | CellCentric Ltd.INDUSTRY | 5 | Jun 24, 2026 | clinicaltrials |
| NCT06713369 | AZD5305 hADME in Patients With Advanced Solid Malignancies(AZD5305) | recruiting | Phase 1 | 8 | AstraZenecaINDUSTRY | 1 | Jun 24, 2026 | clinicaltrials |
| NCT03363893 | Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies | completed | Phase 1 / Phase 2 | 124 | Carrick Therapeutics LimitedINDUSTRY | 2 | Jun 23, 2026 | clinicaltrials |
| NCT04277637 | Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies | active not recruiting | Phase 1 | 437 | BeOne MedicinesINDUSTRY | 7 | Jun 22, 2026 | clinicaltrials |
| NCT04581512 | Study to Evaluate the Safety and Tolerability of EP0042 | recruiting | Phase 1 / Phase 2 | 70 | Ellipses PharmaINDUSTRY | 3 | Jun 22, 2026 | clinicaltrials |
| NCT04857372 | A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors | active not recruiting | Phase 1 | 137 | Novartis PharmaceuticalsINDUSTRY | 11 | Jun 22, 2026 | clinicaltrials |
| NCT05325866 | A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression(FORTITUDE-301) | terminated | Phase 1 / Phase 2 | 260 | AmgenINDUSTRY | 26 | Jun 22, 2026 | clinicaltrials |
| NCT05573126 | Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer | recruiting | Phase 1 / Phase 2 | 95 | Ellipses PharmaINDUSTRY | 3 | Jun 22, 2026 | clinicaltrials |
| NCT06545331 | Study of XB010 in Subjects With Solid Tumors | recruiting | Phase 1 | 396 | ExelixisINDUSTRY | 2 | Jun 22, 2026 | clinicaltrials |
| NCT03132792 | AFPᶜ³³²T in Advanced HCC | completed | Phase 1 | 39 | AdaptimmuneINDUSTRY | 4 | Jun 17, 2026 | clinicaltrials |
| NCT05463263 | A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas | recruiting | Phase 1 / Phase 2 | 180 | Step Pharma, SASINDUSTRY | 3 | Jun 16, 2026 | clinicaltrials |
| NCT06297525 | Study of STP938 (Dencatistat) in Advanced Solid Tumours | recruiting | Phase 1 | 70 | Step Pharma, SASINDUSTRY | 3 | Jun 16, 2026 | clinicaltrials |
| NCT02671435 | A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 383 | MedImmune LLCINDUSTRY | 11 | Jun 15, 2026 | clinicaltrials |
| NCT05563220 | Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer(ELEVATE) | active not recruiting | Phase 1 / Phase 2 | 435 | Stemline Therapeutics, Inc.INDUSTRY | 13 | Jun 12, 2026 | clinicaltrials |
| NCT07346144 | Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma(ADePT) | recruiting | Phase 1 / Phase 2 | 68 | Trogenix ltdINDUSTRY | 2 | Jun 12, 2026 | clinicaltrials |
| NCT07643870 | Human ADME Study of [14C]-AZD1390 | not yet recruiting | Phase 1 | 8 | AstraZenecaINDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT04106115 | DURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancEr(DURANCE) | recruiting | Phase 1 / Phase 2 | 52 | University College, LondonOTHER | 1 | Jun 11, 2026 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials